09:35*09:55! Diagnostics! Elias!Campo!(Barcelona)!
!
09:55*10:15! First!line!treatment! Steven!Le!Gouill!(Nantes)!
!
10:15*10:35! Salvage!treatment! Martin!H.!Dreyling!(Munich)!
/
10:35*10:55! BTK!failures! Olivier!Hermine!(Paris)/ /
(
10:55*11:00! TP53/status/in/Mantle/Cell/Lymphoma/(MCL)/M/a/10Myear// Ezzat/Elhassadi/(Waterford)/
/ single/center/experience/
(
11:00*11:25! Discussion/Q/&/A/
!!
11:25*13:05! Lunch!
!!
13:05*15:00((( SESSION(VI(–(Diffuse(Large(B_Cell(Lymphoma(
(((((((((((((( Chairs:(Catherine(Thieblemont((Paris)(and(Davide(Rossi((Bellinzona)(
!
13:05*13:10! Introduction!
!
13:10*13:30! Diagnostics! Thierry!Molina!(Paris)!
!
13:30*13:50! First!line! Andy!Davies!(Southampton)!
!
13:50*14:10! Relapse! Jason!Westin!(Houston)!
/
14:10*14:30! CAR!–!T!cells! Stephen!Schuster!(Philadelphia)!
!
14:30*14:35! Improved/personalized/survival/prediction/of/patients/with// Miguel/Cid/López/(Santiago/de/Compostela)/
/ diffuse/large/bMcell/lymphoma/using/gene/expression/profiling!
!
14:35*15:00( Discussion/Q/&/A//
!
15:00*15:45! Key(Note(Lecture:(Biology(and(New(Targets(in(DLBCL(( Riccardo!Dalla!Favera!(New!York)((
!
15:45*15:50! Discussion/
((
!
15:!/
50*16:50! !SATELLITE(SYMPOSIUM! !
(
(How(I(treat(relapsed/refractory(disease(–(DLBCL(and(CLL(
( (Chair:(Gilles!Salles!(New!York)!
( (Speakers:(Marie*Jose!Kersten!(Amsterdam),!Kieron!Dunleavy!(Washington),!!
! ! Francesc!Bosch!(Barcelona),!Astrid!Pavlosky!(Buenos!Aires)!
( (
This/educational/symposium/is/organized/and/funded/by/the/Lymphoma/Hub/
(!
!
16:55*17:50( DEBATE(III:(Do(we(still(need(ASCT(in(MCL?((
( Chair:(Olivier(Hermine((Paris)(
5
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES